Facebook Tracking Image

National Comprehensive Cancer Network

About NCCN

NCCN Oncology Research Program Celebrates 10th Anniversary by Closing in on $20 Million in Funding; Program Expands into Developmental Therapies

The NCCN Oncology Research Program (ORP) nears the $20 million mark in total funding and enhances its current model to include funding for therapeutics in development as well as those already FDA-approved. The ORP draws on the expertise of investigators at 21 of the world’s leading cancer centers (NCCN Member Institutions) in order to advance therapeutic options for patients with cancer.

April 29, 2009

FORT WASHINGTON, PA — The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) recently marked its 10 year anniversary by announcing that it is close to achieving $20 million in total funding since the inception of the program. The ORP also announced a new research model that expands their research focus into drugs in development to complement the current model that provides funding for FDA-approved therapies.

“NCCN is thrilled to have attained nearly $20 million in funding for research that seeks to reduce cancer-related deaths and improve the quality of life for patients by advancing innovative therapies through clinical trials at NCCN Member Institutions,” says William T. McGivney, PhD, Chief Executive Officer, NCCN. “By expanding the program to include therapies in development, NCCN continues to enhance its role in furthering the science of oncology by offering a more comprehensive set of services.”

The NCCN ORP is organized to obtain funding to support investigator-initiated trials at NCCN Member Institutions that explore new avenues of clinical investigation to answer important scientific questions. Studies evaluate innovative combinations and sequencing regimens of drugs, mechanisms of action of specific agents, drug resistance, and extended uses for specific agents.

In addition to developing a successful model to support research enterprises at NCCN Member Institutions, the NCCN ORP organizes scientific advisory boards to evaluate potential uses of promising agents and provide expert advice on the best avenues of research to pursue.

The NCCN ORP was developed in 1999 and was initially named the Clinical Trials Network before evolving into the Oncology Research Program in 2005. By building a centralized clinical trials infrastructure in which supporters have access to premier experts and investigators at 21 of the world’s leading cancer centers, NCCN looks to continue to provide patients with promising treatment through state-of-the-art clinical research trials.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 30 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world.

The NCCN Member Institutions are:

  • Abramson Cancer Center at the University of Pennsylvania
  • Fred & Pamela Buffett Cancer Center
  • Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
  • City of Hope National Medical Center
  • Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center
  • Duke Cancer Institute
  • Fox Chase Cancer Center
  • Huntsman Cancer Institute at the University of Utah
  • Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
  • Mayo Clinic Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • Moffitt Cancer Center
  • The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
  • O'Neal Comprehensive Cancer Center at UAB
  • Roswell Park Comprehensive Cancer Center
  • Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
  • St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
  • Stanford Cancer Institute
  • UC San Diego Moores Cancer Center
  • UCLA Jonsson Comprehensive Cancer Center
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • University of Colorado Cancer Center
  • University of Michigan Rogel Cancer Center
  • The University of Texas MD Anderson Cancer Center
  • University of Wisconsin Carbone Cancer Center
  • UT Southwestern Simmons Comprehensive Cancer Center
  • Vanderbilt-Ingram Cancer Center
  • Yale Cancer Center/Smilow Cancer Hospital